Panion & BF Biotech Inc.

Panion & BF Biotech Inc. (PBF) is a prominent Taiwanese biopharmaceutical company founded in 1976. The company operates as a fully integrated healthcare platform, spanning drug discovery, clinical development, cGMP manufacturing, and global commercialization. PBF is organized into four core business groups: Disease Treatment (Nephrology), Disease Prevention (Infection Control), Disease Diagnosis (IVD), and Anti-Aging (Medical Aesthetics). The company's flagship achievement is the development of Nephoxil (Ferric Citrate), a novel phosphate binder for chronic kidney disease (CKD) patients. Nephoxil is marketed globally through strategic partnerships, notably as Auryxia in the United States (licensed to Akebia/Keryx) and Riona in Japan (licensed to Japan Tobacco/Torii Pharmaceutical). PBF also maintains a strong presence in the medical aesthetics market with its 'Hair Gene' and 'Siha Mina' brands, and was a key provider of COVID-19 rapid antigen tests in Taiwan.